Scientific Programme   ›Download Final Programme (PDF 1,7MB)   ›Programme at a Glance ›Wednesday, December 3rd ›Thursday, December 4th ›Friday, December 5th ›Saturday, December 6th ›Authors Index Friday, December 5th 09.00 – 10.30 hrs. EMERGING INFECTIONS AND PANDEMIC Chair: H. Burgmann (Vienna, Austria) H. Hrabcik (Vienna, Austria) 014 Pandemic Preparedness in the EU- Current Status and Challenges (20 Min.) R. Snacken, P. Kreidl, A. Nicoll Stockholm, Sweden 015 Austrian Pandemics Plan (20 min.) H. Hrabcik Vienna, Austria 016 Pandemic/Emergent Diseases (20 Min.) A. Melico-Silvestre Coimbra, Portugal 017 Tuberculosis and HIV in East Europe (20 Min.) P. Khaykin Frankfurt am Main, Germany 10.30 – 11.00 hrs. Coffee Break (With the kind support of Sanofi-Aventis GmbH)   11.00 – 12.30 hrs. VIRAL UPDATE Chair: M. Peck-Radosavljevic (Vienna, Austria) S. Sidorenko (Moscow, Russia) 018 Current Management of Chronic Hepatitis B (15 Min.) M. Peck-Radosavljevic Vienna, Austria 019 Management of Chronic Hepatitis C. An Up-Date (15 Min.) H. Laferl Vienna, Austria 020 HIV Therapy. An Up-Date (15 Min.) N. Vetter Vienna, Austria 021 Switching of Double-boosted Protease Inhibitor (PI) Regimen to Single-boosted PI Regimen in HIV-infected Patients with Multi-NRTI and NNRTI Resistance (10 Min.) S. Sungkanuparph, S. Kiertiburanakul, B. Piyavong, W. Manosuthi Bankgkok, Thailand 022 Anticancer and Antiviral Activities of Structural Isoform RtH2 of Native Hemocyanin, Derived from the Bulgarian Sea Mollusk Rapana Thomasiana (10 Min.) P. Genova-Kalou, K. Idakieva, D. Dundarova, A. Tchorbanov, R. Argirova Sofia, Bulgaria 023 Viral Infection and Immunosuppression in Rheumatic Diseases (10 Min.) O.N. Yegorova, R.M. Balabanova, E.G. Sazina Moscow, Russia With the kind support of Gilead Sciences GmbH   12.30 – 14.00 hrs. Lunch Break PFIZER SYMPOSIUM:   UPDATE ON STRATEGIES AGAINST LIFE-THREATENING INFECTIONS Exotoxins of Staphylococcus Aureus H. Lagler Vienna, Austria Staphylococcus Infections: an Update on Therapeutic Strategies O. Janata Vienna, Austria Invasive Aspergillosis in the ICU H. Burgmann Vienna, Austria 14.00 – 15.30 hrs. ÖGACH SYMPOSIUM I: OPTIMIZED ANTIMICROBIAL THERAPY – WHAT DOES THE ANTIBIOGRAM CONTRIBUTE? Chair: P. Apfalter (Linz, Austria) W. Graninger (Vienna, Austria) 024 About Susceptibility Testing and Breakpoints - a Microbiologists Viewpoint (15 Min. + 5 Min. Disc.) P. Apfalter Linz, Austria 025 How Breakpoints Arise - the Pharmacological Point of View (20 Min. + 5 Min. Disc.) M. Zeitlinger Vienna, Austria 026 Challenge and Pitfalls by Utilizing AUC/MIC and Other PK/PD Parameters (20 Min. + 5 Min. Disc.) Ch. Joukhadar Boston, USA 027 Is MRSA More Pathogenic than MSSA? Differences in the Frequency and Combinations of Virulence Genes between MRSA and MSSA Strains (15 Min. + 5 Min. Disc.) F. Rozgonyi Budapest, Hungary 15.30 – 16.00 hrs. Coffee Break (With the kind support of Wyeth Lederle Pharma GmbH)   16.00 – 17.30 hrs. ÖGACH SYMPOSIUM II: OPTIMIZED ANTIMICROBIAL THERAPY – WHAT DOES THE ANTIBIOGRAM CONTRIBUTE? Chair: P. Apfalter (Linz, Austria) W. Graninger (Vienna, Austria) 028 Antibiogram and Clinical Consequences. The Real Life I - Case Report(s) (15 Min. + 5 Min. Disc.) O. Janata Vienna, Austria 029 Antibiogram and Clinical Consequences. The Real Life II - Case Report(s) (20 Min. + 5 Min. Disc.) W. Graninger Vienna, Austria 030 Bacteremia with ESBLs-Producing Enterobacteriaceae an Emerging Challenge (20 Min. + 5 Min. Disc.) E. Keuleyan Sofia, Bulgaria 031 Antibiotic Resistant Escherichia Coli Strains are Inherited from Parents and Persist in the Infants´ Intestines in the Absence of Selective Pressure (10 Min. + 5 Min. Disc.) D. Orth, M. Prelog, K. Grif, M.P. Dierich, R. Würzner Innsbruck, Austria With the kind support of the „Austrian Society for Antimicrobial Chemotherapy – ÖGACH“     ›Download Final Programme (PDF 1,7MB)   ›Programme at a Glance ›Wednesday, December 3rd ›Thursday, December 4th ›Friday, December 5th ›Saturday, December 6th ›Authors Index   Print this page top Scientific Programme

	13th Scientific Meeting of the European Society of Chemotherapy/ Infectious Diseases December 3rd-6th, 2008

www.escid.org/2008